Mepact
Mepact wins NICE backing
October 26, 2011Research and Development, Sales and Marketing Mepact, NICE
NICE has recommended Takeda’s bone cancer drug Mepact after the firm offered a discount for the treatment. The watchdog’s final …
NICE recommends Takeda’s cancer drug Mepact
September 7, 2011Sales and Marketing Mepact, NICE, Takeda
NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
NICE unmoved on Takeda bone cancer drug
October 13, 2010Sales and Marketing Mepact, NICE, Takeda
NICE has refused to recommend Takeda’s Mepact because of its “exceptionally high cost” and the “substantial uncertainty” about the osteosarcoma …
NICE rejects Takeda cancer drug over price concerns
July 12, 2010Sales and Marketing Cancer, Mepact, NICE, Takeda, bone cancer
UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …
